Business Description

Titan is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

ProNeura consists of a small, solid implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is administered subdermally, normally in the inner upper arm, in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.

Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. For additional information regarding Probuphine, click here.

Officers & Directors

name

Kate Beebe DeVarney, Ph.D.

President and Chief Operating Officer

Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer.  She previously served as Chief Scientific Officer and has been with the…

View Full Bio
name

Marc Rubin, MD

Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,…

View Full Bio
name

Kate Beebe DeVarney, Ph.D.

President and Chief Operating Officer

Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer.  She previously served as Chief Scientific Officer and has been with the…

View Full Bio
name

Joseph A. Akers

Mr. Akers has served as president of Bayer's hematology/cardiology business, where he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also…

View Full Bio
name

M. David MacFarlane, PhD

Dr. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to…

View Full Bio
name

James R. McNab, Jr.

Mr. McNab, an entrepreneur experienced in building and growing companies, is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor…

View Full Bio

David E. Lazar

Interim Chairman of the Board of Directors and Chief Executive Officer

Mr. Lazar serves as Titan’s Interim Chairman of the Board of Directors and Chief Executive Officer. He previously served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed…

View Full Bio

Avraham Ben-Tzvi

Mr. Ben-Tzvi is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments & Securities Laws, Commercial…

View Full Bio

Eric Greenberg

Mr. Greenberg has over 40 years of capital markets experience. As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring. Mr.…

View Full Bio

David Natan

Mr. Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, since 2007. In…

View Full Bio

Matthew C. McMurdo

Mr. McMurdo currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010. Previously, Mr. McMurdo was a Partner at Nannarone & McMurdo, LLP, a boutique law firm, from 2008 to 2010. In…

View Full Bio

Peter L. Chasey

Mr. Chasey serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation, business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff…

View Full Bio

IR Contact Information

Investor Relations
Stephen Kilmer
T: 650-989-2215
skilmer@titanpharm.com